Resource Summary Report

Generated by NIF on Sep 8, 2026

NCI-H841

RRID:CVCL_1595
Type: Cell Line

Proper Citation

RRID:CVCL_1595

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1595

Proper Citation: RRID:CVCL_1595

Description: Cell line NCI-H841 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Thoracic SMARCA4-deficient undifferentiated tumor

Defining Citation: PMID:8784480, PMID:8806092, PMID:8806103, PMID:10536175, PMID:11005564, PMID:11030152, PMID:19472407, PMID:20215515, PMID:20557307, PMID:22460905, PMID:22961666, PMID:23716474, PMID:25877200, PMID:27247353, PMID:27397505, PMID:28766886, PMID:30894373, PMID:31068700, PMID:31803961, PMID:32586373, PMID:38180245, PMID:39154123

Comments: Caution: Originally classified as originating from a lung small cell carcinoma, but is reclassified as a thoracic SMARCA4-deficient undifferentiated tumor based on a number of criteria (PubMed=38180245)., Population: Caucasian., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H841

Synonyms: H841, H-841, NCI-841, NCIH841

Cross References: CLO:CLO_0008122, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5845, BioSample:SAMN03471025, BioSample:SAMN10988536, cancercelllines:CVCL_1595, Cell_Model_Passport:SIDM01134, Cosmic:801616,

Cosmic:844564, Cosmic:876162, Cosmic:897511, Cosmic:918013, Cosmic:1021871, Cosmic:1032404, Cosmic:1219092, Cosmic:1239941, Cosmic:1891907, Cosmic:2125187, Cosmic-CLP:1240192, DepMap:ACH-000292, EGA:EGAS00001000978, GDSC:1240192, GEO:GSM171888, GEO:GSM171889, GEO:GSM794303, GEO:GSM827488, GEO:GSM844661, GEO:GSM845552, GEO:GSM887449, GEO:GSM888529, GEO:GSM986177, GEO:GSM1670269, GEO:GSM1887922, GEO:GSM1888004, IARC_TP53:11886, KCLB:90841, LiGeA:CCLE_365, LINCS_LDP:LCL-1819, PharmacoDB:NCIH841_1143_2019, Progenetix:CVCL_1595, Wikidata:Q54908131

ID: CVCL_1595

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260905T181247+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H841.

No alerts have been found for NCI-H841.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 10 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Balke-Want H, et al. (2026) c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. Cell reports. Medicine, 7(1), 102549.

Paál Á, et al. (2025) Roles of Annexin A1 Expression in Small Cell Lung Cancer. Cancers, 17(9).

Iñañez A, et al. (2025) The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. International journal of molecular sciences, 26(3).

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, OF1.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. Cell chemical biology, 31(7), 1247.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. Cancer research, 83(9), 1426.

Dexheimer TS, et al. (2023) Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs. Cancer research communications, 3(8), 1648.

Groves SM, et al. (2022) Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. Cell systems, 13(9), 690.

Takahashi N, et al. (2022) Replication stress defines distinct molecular subtypes across cancers. Cancer research communications, 2(6), 503.

Taniguchi H, et al. (2022) WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell reports, 39(7), 110814.